Clinical Trial Update: An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. [Phase 3]

View source ↗

Summary

Phase 3 open-label study evaluating fixed-dose durvalumab + tremelimumab vs durvalumab alone in advanced solid malignancies; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Malignancies

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Malignancies | Phase 3 | Status: COMPLETED | Results posted: 2021-06-15